StockNews.AI
ANIX
StockNews.AI
169 days

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

1. Dr. Garzone to present at ACGT Summit 2025 on cancer therapies. 2. Anixa's CAR-T therapy for ovarian cancer will be discussed. 3. Panel discussion aims to drive discussions on gene-based cancer treatments. 4. Event unites experts in cell and gene therapies for solid tumors. 5. Anixa collaborates with leading institutions for cancer treatment innovations.

6m saved
Insight
Article

FAQ

Why Bullish?

Participation in high-profile events like the ACGT Summit raises Anixa's visibility and credibility, which can attract investment. Historical examples show that biotech companies often see stock price appreciation around significant conferences and presentations.

How important is it?

The conference provides a platform for Anixa to showcase its advancements and engage with potential partners and investors. Thus, it holds substantial potential to influence both market perception and investor behavior.

Why Short Term?

The immediate interest generated by conference participation typically results in short-term stock movement. Events like this can quickly shift investor sentiment and create trading opportunities over the following weeks.

Related Companies

MCRBGILDNVAX
SAN JOSE, Calif., March 3, 2025 /PRNewswire/ -- Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Pam Garzone, Chief Development Officer of Anixa, will be attending the Alliance for Cancer Gene Therapy (ACGT) Summit 2025 and participating as a panelist on the Gynecologic and Breast Cancers panel. The Alliance for Cancer Gene Therapy Summit 2025 is being held on Wednesday and Thursday, March 19 - 20, 2025, at the Alexandria Center for Life Science in New York City. Dr. Garzone will join leading experts in the field to discuss advancements in cell and gene therapy, including Anixa's CAR-T therapy for ovarian cancer, and its potential impact on gynecologic and breast cancers. The panel is scheduled for Wednesday, March 19, 2025, from 11:15 AM – 12:15 PM ET. Dr. Amit Kumar, Chairman and CEO of Anixa, stated, "We are pleased that Anixa and Dr. Garzone were invited to share insights at the ACGT Summit. Our discussions and contributions to the development of novel cancer therapies will help drive meaningful discussions on the future of gene-based treatments for gynecologic and breast cancers." The Alliance for Cancer Gene Therapy Summit 2025 will bring together leading physician scientists advancing research to develop curative cell and gene therapies for solid tumor cancers. For more information about the conference, visit Alliance for Gene Therapy Summit 2025. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFO[email protected]408-708-9808 SOURCE Anixa Biosciences, Inc.

Related News